



**BACKGROUND:**

Challenging target: RNA-binding protein which should be targeted by allosteric mechanism only to avoid unspecific off-target effects. Only a few known allosteric inhibitors exist. Two previously unknown allosteric binding pockets were identified by Receptor.AI's proprietary pocket detection AI model.

**METHODOLOGY:**

Virtual Screening result: Enamine common stock collection of 1.4 million compounds was screened. 1000 ranked candidate compounds were prioritized. 209 of them were selected for experimental validation.



1.4 M
compounds screened

209
hit candidates selected

4
potent compounds identified


18x
interferon induction by lead-like compound

RESULTS:


Biological validation: The experimental validation was performed using a high throughput p110 knockout cell-based assay. The criteria for a hit compound was established as a 5-fold increase in interferon induction compared to the control, with the desirable outcome being a 10-fold increase in interferon induction to surpass the efficacy of siRNA alternatives. In this assay, 4 hit compounds were identified, and their ability to induce interferons was confirmed across various cell lines, including A549 p110 KO, HCT116, and B16F10.

Hit compounds: Hit compounds were validated by the dose-response analysis. Two of them exhibit comparable or superior maximal interferon induction with lower EC₅₀ in comparison to a competing compound. This was achieved on a much 2.5 times smaller screening library (209 against 500 for competitors). Active scaffolds have been selected for further series expansion and optimization.


Compound	Fold interferon induction, 25 μ M	EC 50, μ M
#1	13.8	13.2
#2	18.9	16.4
#3	10.7	22.1
#4	8.6	38.0
Competitor #1	14.1	17.5



Dose-Response relationship for Compound #1, #2 and Competitor compound #1



The binding pose for the compound #2 mentioned above



Interferon induction observed at 25 μ M for Receptor.AI hit compounds #(1-4) obtained through virtual screening, a competitor small molecule, and ADAR1 siRNA